Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. In cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 53% of the company's 2025 sales were generated from US human health (pharmaceuticals and vaccines).
Last trade$143.46
Day change-$1.005 (-0.70%)
Day range$142.37 – $145.05
Volume3,761,704
Market cap$356.13B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$356.13B
Price / earnings
145.18×
Price / book
7.93×
Price / sales
5.29×
EV / sales
5.94×
EV / EBITDA
29.56×
Profitability
Earnings per share
$1.00
Return on assets
1.85%
Return on equity
5.46%
Dividend yield
2.35%
Liquidity and leverage
Debt / equity
1.2×
Current ratio
1.35×
Quick ratio
1.14×
Cash ratio
0.33×
Cash flow
Price / cash flow
19.04×
Price / free cash flow
24.15×
Free cash flow
$14.75B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for MRK, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$18.09B
$16.61B
$16.29B
$16.4B
$17.28B
$15.81B
$15.53B
$15.62B
Cost of revenue
$4.89B
$4.4B
$4.2B
$5.55B
$3.86B
$3.56B
$3.42B
$3.83B
Gross profit
$13.19B
$12.21B
$12.09B
$10.85B
$13.42B
$12.25B
$12.11B
$11.8B
Selling, general and administrative
$2.89B
$2.9B
$2.7B
$2.9B
$2.63B
$2.65B
$2.55B
$2.86B
Research and development
$4.54B
$9.74B
$12.59B
$3.89B
$4.23B
$4.05B
$3.62B
$4.58B
Total operating expenses
$7.61B
$12.8B
$15.49B
$7B
$6.91B
$7.26B
$6.24B
$7.5B
Operating income
$5.59B
-$584M
-$3.4B
$3.85B
$6.51B
$4.99B
$5.87B
$4.3B
Interest expense
-$546M
-$525M
$0
$0
-$327M
-$305M
$0
$0
Income before taxes
$5.56B
-$683M
-$3.53B
$3.42B
$6.75B
$5B
$5.9B
$4.17B
Income taxes
$492M
$654M
$709M
$458M
$958M
$571M
$818M
$426M
Net income
$5.07B
-$1.34B
-$4.24B
$2.96B
$5.79B
$4.43B
$5.09B
$3.74B
Net income attributable to common shareholders
$5.07B
-$1.34B
-$4.24B
$2.96B
$5.79B
$4.43B
$5.08B
$3.74B
EBITDA
$7.55B
$1.15B
-$1.69B
$6.53B
$7.71B
$6.67B
$7.04B
$5.55B
Basic earnings per share
$2.05
-$0.54
-$1.72
$1.19
$2.32
$1.76
$2.01
$1.48
Diluted earnings per share
$2.04
-$0.54
-$1.72
$1.19
$2.32
$1.76
$2.01
$1.48
Recent news
Company coverage with links to the original publishers.
Over 200 companies are advancing cancer vaccine development with 200+ pipeline candidates in clinical trials. Recent positive Phase III results for intismeran autogene (mRNA-4157) in melanoma and encouraging data for TG4050 in head and neck cancer are driving momentum. However, challenges including clinical efficacy uncertainties, manufacturing complexity, high production costs, and patient selection barriers remain obstacles to broader commercialization.
The global biotechnology market, valued at USD 2.02 trillion in 2026, is projected to reach USD 6.34 trillion by 2035 at a 13.61% CAGR. Leading biotech companies including Amgen, Gilead, Regeneron, Vertex, and Moderna reported strong Q3 2026 results with revenue growth ranging from 8% to 36%. The sector experienced record dealmaking activity with major acquisitions totaling tens of billions of dollars, driven by patent expiries, strong cash flows, and strategic pipeline expansion in oncology, immunology, and advanced therapies.
AstraZeneca reported Q3 2026 revenues of $16.21 billion (up 7% YoY) and core EPS of $2.79, beating consensus estimates. Strong oncology sales growth (16% to $21.9B) and new drug launches support the company's $80 billion 2030 revenue target. However, generic erosion of mature drugs, recent pipeline failures, and China market uncertainties create headwinds. The company maintains mid-to-high single-digit revenue growth guidance for 2026.
Johnson & Johnson announced a $2.2 billion acquisition of clinical-stage biotech Ollin Biosciences to expand its ophthalmology pipeline with OLN324, a phase III bispecific antibody for retinal diseases. Blackstone will fund $750 million of the phase III development. This acquisition is part of J&J's broader strategy of pursuing strategic M&A to strengthen its Innovative Medicine and MedTech businesses, following recent acquisitions of Firefly Bio, Intra-Cellular Therapies, Shockwave Medical, and Abiomed.
Merck's stock has surged nearly 40% in 2026, driven by strong Keytruda revenue including its new subcutaneous formulation Keytruda Qlex. However, the analyst recommends holding off on buying at current levels due to upcoming patent expirations in 2028 and uncertain revenue outlook, despite the stock trading at a modest discount to the S&P 500 average P/E multiple.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Sep 15, 2026
$0.85
Oct 7, 2026
recurring
Jun 15, 2026
$0.85
Jul 8, 2026
recurring
Mar 16, 2026
$0.85
Apr 7, 2026
recurring
Dec 15, 2025
$0.85
Jan 8, 2026
recurring
Sep 15, 2025
$0.81
Oct 7, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.